Sign in
Simran

Simran

Research Analyst at Wells Fargo & Company/mn

Bengaluru, KA, IN

No publicly verifiable information is available about an analyst named Simran at Wells Fargo & Company. Despite a thorough search for LinkedIn and credible financial industry profiles matching this specific query, there is no evidence of a person named Simran holding an analyst or senior analyst role at Wells Fargo, nor any performance data, coverage company details, or recognized professional credentials in public records. If more detailed identity information or alternative name spellings are provided, a more focused search may yield results, but as of now, there is no profile meeting the requested criteria.

Simran's questions to INSULET (PODD) leadership

Question · Q3 2025

Simran, on behalf of Larry Biegelson, asked about the drivers behind the upside in U.S. Omnipod expectations, the sustainability of these underlying trends, and whether record new customer starts should be anticipated on a quarterly basis moving forward.

Answer

Ashley McEvoy, President and CEO, attributed the upside to strong performance in the core U.S. Type 1 business (despite 40% penetration and clinical inertia) and accelerated momentum in Type 2. She highlighted efforts to educate endocrinologists and PCPs on AID guidelines and the impact of direct-to-consumer (DTC) campaigns in generating meaningful leads for Type 2 patients.

Ask follow-up questions

Simran's questions to DEXCOM (DXCM) leadership

Question · Q3 2025

Simran asked about the resolution of G7 performance issues, specifically the 'noise' during the quarter, and whether these issues disrupted new starts or prescribing patterns in Q3, Q4, or 2026.

Answer

Jake Leach, President and Interim CEO, confirmed that G7 quality issues, particularly deployment challenges, have been resolved in the factory, and product quality is now exceptional. Jereme Sylvain, CFO, acknowledged a slight impact on Q3 new starts, but noted strong performance, with expectations for Q4 and 2026 to return to record new customer starts.

Ask follow-up questions

Simran's questions to DENTSPLY SIRONA (XRAY) leadership

Question · Q1 2025

Simran, on for Vik Chopra, asked about the mitigation strategies in place for the guided tariff impact and requested an update on the timing and status of the German tax situation.

Answer

CEO Simon Campion clarified that the current guidance does not yet factor in mitigation efforts, which could include building strategic inventory, product swaps, and prudent expense management. Regarding the German tax issue, he stated that the company continues to cooperate with authorities but cannot predict a resolution timeline, while reiterating confidence in its legal position.

Ask follow-up questions

Best AI for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%
Claude Sonnet 4.555.3%
o348.3%
GPT 546.9%
Grok 440.3%
Qwen 3 Max32.7%